Brian Noga
- Breaking microgram barrier to conduct dose ranging studies with long acting bronchodilators from a novel cosuspension metered dose inhaler product platformBy Vidya Joshi, Brian Noga, David Lechuga-Ballesteros, Robert Schultz, Harris Cummings, Michael Golden, Chad Orevillo, Colin Reisner and Sarvajna DwivediVidya Joshi1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesBrian Noga1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesDavid Lechuga-Ballesteros1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesRobert Schultz1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesHarris Cummings1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesMichael Golden1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesChad Orevillo1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesColin Reisner1Research & Development, Pearl Therapeutics, Inc., Redwood City, United StatesSarvajna Dwivedi1Research & Development, Pearl Therapeutics, Inc., Redwood City, United States
- Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPDBy David Lechuga-Ballesteros, Vidya Joshi, Mark Sommerville, Michael Golden, Reinhard Vehring, Brian Noga, Harris Cummings, Robert Schultz, Chad Orevillo, Colin Reisner and Sarvajna DwivediDavid Lechuga-Ballesteros1Research & Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesVidya Joshi1Research & Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesMark Sommerville2Research & Development, Pearl Therapeutics, Inc., Raleigh, NC, United StatesMichael Golden3Regulatory Affairs & Qualilty, Pearl Therapeutics, Inc., Raleigh, NC, United StatesReinhard Vehring1Research & Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesBrian Noga2Research & Development, Pearl Therapeutics, Inc., Raleigh, NC, United StatesHarris Cummings2Research & Development, Pearl Therapeutics, Inc., Raleigh, NC, United StatesRobert Schultz2Research & Development, Pearl Therapeutics, Inc., Raleigh, NC, United StatesChad Orevillo4Clinical Development, Pearl Therapeutics, Inc., Morristown, NJ, United StatesColin Reisner4Clinical Development, Pearl Therapeutics, Inc., Morristown, NJ, United StatesSarvajna Dwivedi1Research & Development, Pearl Therapeutics, Inc., Redwood City, CA, United States
- Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platformBy David Lechuga-Ballesteros, Vidya Joshi, Brian Noga, Jake Howland, Harris Cummings, Rob Schultz, Chad Orevillo, Colin Reisner and Sarvajna DwivediDavid Lechuga-Ballesteros1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesVidya Joshi1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesBrian Noga1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesJake Howland1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesHarris Cummings1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesRob Schultz1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesChad Orevillo1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesColin Reisner1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesSarvajna Dwivedi1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United States
- Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs)By Brian Noga, David Lechuga-Ballesteros, Vidya Joshi, Rob Schultz, Jake Howland, Harris Cummings, Chad Orevillo, Colin Reisner and Sarvajna DwivediBrian Noga1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesDavid Lechuga-Ballesteros1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesVidya Joshi1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesRob Schultz1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesJake Howland1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesHarris Cummings1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesChad Orevillo1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesColin Reisner1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United StatesSarvajna Dwivedi1Pharmaceutical and Clinical Development, Pearl Therapeutics, Inc., Redwood City, CA, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.